What is Antengene?
Antengene is a commercial-stage, R&D-driven biopharmaceutical organization dedicated to the development of innovative medicines for cancer and life-threatening diseases. Since its inception in 2017, the company has established a formidable presence in the global market, leveraging both in-house discovery and strategic partnerships to build a pipeline of 15 clinical and pre-clinical assets. By focusing on high-unmet-need therapeutic areas, Antengene has successfully obtained 23 investigational new drug approvals and secured multiple new drug application approvals for its flagship product, XPOVIO, across key markets including China, South Korea, Singapore, and Australia. The firm operates with a clear vision of treating patients beyond borders, utilizing its integrated platform to bridge the gap between advanced scientific research and clinical application.
How much funding has Antengene raised?
Antengene has raised a total of $238M across 3 funding rounds:
Series A
$21M
Series B
$120M
Series C
$97M
Series A (2017): $21M with participation from TF Capital, Huagai Capital, Qiming Venture Partners, and Tigermed
Series B (2019): $120M led by Boyu Capital
Series C (2020): $97M supported by Fidelity Management & Research Company, Qiming Venture Partners, GL Ventures, GIC, and Boyu Capital
Key Investors in Antengene
Fidelity Management & Research Company
A global financial services leader providing comprehensive investment, wealth management, and advisory solutions to institutional and individual clients.
GIC
A prominent sovereign wealth fund managing Singapore's foreign reserves through diversified investments across public and private global markets.
Boyu Capital
A leading alternative asset management firm specializing in private equity and venture capital with a strong focus on the healthcare and technology sectors.
What's next for Antengene?
Looking ahead, Antengene is positioned to leverage its substantial capital reserves to transition from a clinical-stage developer to a fully integrated commercial powerhouse. The strategic focus remains on the continued expansion of its therapeutic portfolio and the acceleration of its regulatory roadmap in the Asia-Pacific region. By maintaining a rigorous commitment to innovation and operational excellence, the company is well-equipped to navigate the complexities of the global biopharmaceutical landscape. Future growth will likely be driven by the commercialization of its existing pipeline and the pursuit of new, high-impact therapeutic programs that address the evolving needs of oncology patients worldwide.
See full Antengene company page
